By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

RegeneRx Biopharmaceuticals, Inc. 

3 Bethesda Metro Center, Suite 630

Bethesda  Maryland  20814  U.S.A.
Phone: 301-280-1992 Fax: 301-280-1996


SEARCH JOBS








Company News
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Allowance For Key Dry Eye Patent In U.S. 9/13/2017 8:55:20 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Completes License Expansion For RGN-137 In Europe, S. Korea, Japan, Canada And Australia 8/31/2017 8:26:30 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Collaborators Receive Notice Of 'Intent To Grant' EU Patent For The Treatment Of Peripheral Neuropathy 8/14/2017 7:27:58 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Updates On RGN-259 Phase 3 Dry Eye Trial 7/27/2017 9:15:54 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Collaborators Receive Notice Of Allowance Of U.S. Patent For The Treatment Of Peripheral Neuropathy 6/13/2017 7:14:20 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) JV Presents Results Of Phase IIb/III (ARISE-1) Dry Eye Trial At Association for Research in Vision & Ophthalmology 2017 5/9/2017 8:13:52 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Releases Annual Letter To Shareholders 3/13/2017 9:11:43 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Licensee Receives FDA Permission To Conduct A Phase III Trial Of RGN-137 For Epidermolysis Bullosa In U.S. 2/27/2017 6:43:35 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Acceptance for Patent in Australia For Treatment of Neural Injury with Thymosin Beta 4. 1/9/2017 8:29:39 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Intent To Grant Patent In EU For Treating Neural Injury With Thymosin Beta 4 12/16/2016 8:00:54 AM
12345678910...
//-->